4^TH Central European Biomedical Congress

days

hours

minutes

seconds

Welcome
address

Dear Friends and Colleagues,

We closely monitored the development related to COVID-19 and in the light of the update, we decided to postpone the 4^th Central European Biomedical Congress (CEBC) to 7-9 June 2021. The motto of the 4^th CEBC Virtual remains valid and reads: The Impact of bioinformatics and omics on biology and medicine.

This congress is jointly organized by the Maj Institute of Pharmacology Polish Academy of Sciences and the Faculty of Medicine, Jagiellonian University Medical College.

Through a series of virtual plenary lectures, oral sessions, poster sessions and workshops, industry-sponsored symposia and exhibitions, 4^th CEBC will provide new information about use of the latest advances in biological and medical sciences, novel technologies such as “multi-omics”, mobile applications, augmented reality and neural networks.

The Congress also will promote outstanding opportunities for junior scientists to present research and interact with leaders in the field, including awardees of European Research Council grants.

Adopting a highly multidisciplinary approach, the Congress aims to draw participation of clinicians, pharmacologists, biologists, bioinformaticians and chemists, sharing the common goal to promote international scientific cooperation and to exchange of ideas and concepts.

We are convinced the Congress will be a memorable event.

Once again we would like to cordially invite to join us at the 4^th CEBC, and we look forward to welcoming you in 2021!

We hope everybody stays safe and look forward to seeing you on the new event date!

Best regards,

On behalf of the Organizing Committee

Małgorzata Filip

Maj Institute of Pharmacology
Polish Academy of Sciences
Krakow

Joanna Pera

Faculty of Medicine
Jagiellonian University, College Medicine
Krakow

Dołącz do wydarzenia na

About the Event

CEBC 2021 is dedicated to:

clinicians, physicians, pharmacologists, biologists, bioinformaticians and chemists.

Plenary
speakers

Professor, David E. Nichols, PhD

Purdue University College of Pharmacy,
West Lafayette, LA, USA

Plenary lecture:
Psychedelic Research in the 21st Century

More

✖

Professor, David E. Nichols, PhD

David E. Nichols, PhD is currently an Adjunct Professor in the Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill, NC. He is a Distinguished Professor Emeritus at the Purdue University College of Pharmacy and was the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology, where he carried out teaching and research for 38 years prior to his retirement in 2012. In 2004 he was named the Irvine H. Page Lecturer by the International Society for Serotonin Research, he received the first Purdue Provost’s Outstanding Graduate Mentor award in 2006, and was named a Distinguished Alumnus by the University of Iowa College of Pharmacy in 2012. He began studying psychedelics in 1969 while a graduate student and continued that research throughout his entire professional career, being one of only a few investigators able to research psychedelics after they were scheduled. In 1993 he founded the Heffter Research Institute (HRI), which funded the first rigorous clinical studies of psychedelics in humans after a nearly 40-year moratorium and served as its president for more than 25 years. HRI funded the groundbreaking Phase I and II studies of psilocybin for the treatment of depression, as well as substance use disorders. Dr. Nichols also synthesized the DMT used by Dr. Rick Strassman in his human studies, the MDMA that MAPS used for their Phase I and II clinical trials for PTSD, and the psilocybin used by several investigators for human clinical studies including the Phase I and II trials conducted at Johns Hopkins University by Roland Griffiths and his colleagues. He is considered the world’s leading expert on the chemistry of psychedelics. Dr. Nichols, although officially retired, remains active in the field through consulting and collaborations with several academic and pharmaceutical organizations and continues to publish scientific papers.
Professor, Francesco Pavone, PhD

European Laboratory for Non Linear Spectroscopy
and Department of Physics,
University of Florence, Italy

Inaugural lecture:
Human brain optical mapping

✖

Professor, Francesco Pavone, PhD
Professor, Francesco Battaglia, PhD

the Donders Institute for Brain, Cognition and Behaviour,
Radboud University, Nijmegen, The Netherlands

Plenary lecture:
The lifetime of memories: processing and reprocessing of information in the brain

✖

Professor, Francesco Battaglia, PhD
Professor, Jacek R. Wiśniewski, PhD

Research Department Proteomics and Signal Transduction,
Max Planck Institute of Biochemistry, Martinsried, Germany

Plenary lecture:
Large scale proteomics for understanding biological systems

✖

Professor, Jacek R. Wiśniewski, PhD

Speakers

Natalia Alenina

Max Delbruck Center for Molecular Medicine,
Berlin, Germany

✖

Natalia Alenina
Marian Bubak

Sano Centre for Computational Medicine, Krakow and AGH University of Science and Technology,
Krakow, Poland

✖

Marian Bubak
Lucia Caffino

Università degli Studi di Milano,
Milano, Italy

✖

Lucia Caffino
Francesca Calabrese

Associate Professor at the Department of Pharmacological and Biomolecular Sciences,
University of Milan, Italy

More

✖

Francesca Calabrese

Francesca Calabrese is currently Associate Professor at the Department of Pharmacological and Biomolecular Sciences (University of Milan). She got her degree in Pharmaceutical Chemistry and Technology at the University of Milan in 2003. In the same University, she got her PhD in Pharmacotoxicological, Pharmacognostic Sciences and Pharmacological Biotechnologies at the Faculty of Pharmacy in 2007 discussing a thesis entitled ‘Involvement of the neurotrophin BDNF in the mechanism of action of antidepressant drugs and in animal models of mood disorders’. In 2007 she was awarded the fellowship ‘Borsa di perfezionamento all’estero’ in order to develop a project at the Zentralinstitut für Seelische Gesundheit-Univ Heidelberg, (Mannheim, Germany). Her scientific interest is focused on the study of psychiatric disorders pathogenesis. The experimental approach is intended to investigate the systems that can contribute to the development of such diseases through the use of animal models (genetic and environmental), as well as to characterize the mechanism of action of psychotropic drugs. She is principal investigator of 8 competitive grants (national and international). She is co-author of 67 peer-reviewed papers, 48 as first, second or last author (H-index= 30, Number of citations= 2673) She attended several international meetings and presented several posters and oral communications on her research. During these years, she received fellowship awards, travel grants and poster prizes.
Anna Ceglarek

Jagiellonian University,
Krakow, Poland

✖

Anna Ceglarek
Adrian Chrobak

Jagiellonian University Medical College,
Krakow, Poland

✖

Adrian Chrobak
Giulia Costa

University of Cagliari,
Cagliari, Italy

✖

Giulia Costa
Wiesław J. Cubala

Medical University of Gdansk,
Gdansk, Poland

More

✖

Wiesław J. Cubala

Wiesław Jerzy Cubała is the Head of the Department of Psychiatry at the Medical University of Gdansk, Poland. His research interests focus on the psychopharmacology of anxiety and mood disorders with a particular interest in ketamine/esketamine use in depression as well as the serotonin-1A receptor function in major depression and panic disorder. Prof. Cubała runs a project on monoaminergic, proinflammatory activity measures and cognitive performance in mood and anxiety disorders. Currently, he is focussed on the study of ketamine use in major depression and bipolar depression, as well as clozapine use in treatment-resistant bipolar depression with a particular focus on suicidality and the rapid-cycling course of the disorders. Moreover, his research team develops screening tools for people with epilepsy suffering from mental disorders. Prof. Cubała is involved in training initiatives in postgraduate education in psychiatry and cognitive-behavioural therapy, including the development of the treatment guidelines for mood and anxiety disorders for psychiatrists and general practitioners. He is devoted to teaching both the clinical and research aspects of psychopharmacology.
Kathryn A. Cunningham

University of Texas Medical Branch,
Galveston, USA

✖

Kathryn A. Cunningham
Bogdan Draganski

University of Lausanne,
Lausanne, Switzerland

More

✖

Bogdan Draganski

Professor Bogdan Draganski, native Bulgarian, is Consultant Neurologist at the Department of Clinical Neurosciences, University Hospital of Lausanne, Switzerland, Director of the neuroimaging laboratory LREN and of the Departmental MRI platform. After qualifying in Clinical Neurology in Germany he spent time working on computational anatomy research in neurodegenerative and movement disorders at the Institute of Neurology, UCL London, UK followed by research at the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig Germany.

I was trained in state-of-the-art magnetic resonance imaging techniques to investigate brain anatomy correlates of neurological disorders. Using methods that I and colleagues developed, I will enrich these models with features from non-invasive magnetic resonance imaging (MRI) sensitive to brains’ myelin, iron and tissue free water content, to then test for systematic differences across cortico-striatal circuits and along spatial gradients within a given node of the studied networks. I pioneered computational anatomy research in use- dependent brain plasticity, developed and established new methods to understand the underlying biological phenomenon.
Dominika Dudek

Jagiellonian University Medical College,
Krakow, Poland

More

✖

Dominika Dudek

Head of the Department of Psychiatry at the Jagiellonian University Medical College. President Elect of the Polish Psychiatric Association, member of the Scientific Council of the Institute of Psychiatry and Neurology. Organizer of the annual Pharmacotherapy, Psychotherapy and Rehabilitation of Affective Disorders Conference (2017 – XXII edition). Chairwoman of the State Examination Commission in Krakow for psychiatry, member of the Local Organizing Committee of EPA 2019 Warsaw. Editor-in-chief of the journal Psychiatria Polska. Author and co-author of many publications about depression, bipolar disorders. Editor and co-author of several books on psychiatric issues.
Gordana Nedic Erjavec

Ruđjer Bošković Institute,
Zagreb, Croatia

✖

Gordana Nedic Erjavec
Giuseppe Giannotti

University of Colorado Denver,
Aurora, CO, USA

✖

Giuseppe Giannotti
Maciej Giefing

Institute of Human Genetics Polish Academy of Sciences,
Poznan, Poland

✖

Maciej Giefing
Andreas Grabrucker

University of Limerick
Limerick, Germany

More

✖

Andreas Grabrucker

Dr. Grabrucker received his MSc in Biology from the Technical University of Munich (TUM), Germany, and his PhD in Molecular Medicine from Ulm University, Germany. He continued his research in the United States at Stanford University, Stanford School of Medicine. From 2011 to 2016, he was tenure-track Assist. Professor and Executive Director of the Neurocenter of Ulm University. In 2017, he joined the Department of Biological Sciences, at the University of Limerick, Ireland and the Bernal Research Institute. He is now Associate Professor and Cluster lead of the Bio Materials Cluster of the Bernal Institute, a cluster with 20 faculty members and about 60 PhD students and Postdocs. He was also awarded a guest professorship at the University of Modena and Reggio Emilia, Italy, in 2019. Dr. Grabrucker’s major research focus is translational neuroscience in the area of Autism Spectrum Disorders, where he generates model systems to understand neurobiological processes of brain development and function. Since 2009, he has published 13 book chapters and over 58 articles in peer reviewed journals, that were cited over 2900 times. He is also author of the popular science book “Eco-Neurobiology and how the environment shapes our brain” and the first textbook about trace metal research in autism entitled “Biometals in Autism Spectrum Disorders”
Jan Gründemann

University of Basel,
Basel, Switzerland

✖

Jan Gründemann
Judith Homberg

Radboud University, Nijmegen Medical Centre
Nijmegen, the Netherlands

More

✖

Judith Homberg

Judith Homberg, currently professor in Translational Neuroscience, did her PhD in 2004 at the VU Medical Center in Amsterdam. Her thesis focused on individual differences in vulnerability to drug addiction. As postdoc at the Hubrecht Institute in Utrecht she generated and characterized the first knockout rats worldwide. After obtaining a personal grant he moved to the Radboud University Medical Center in Nijmegen to establish her own research group. Her group focusses on (serotonin-dependent) individual differences in behaviour and susceptibility to neurodevelopmental and stress-related disorders. She has strong expertise in behavioural neuroscience and bridges fundamental and clinical research. She obtained Young Investigator prizes from the European Behavioural Pharmacology Society and the International Behavioural and Neural Genetics Society, and several prestigious national and EU-funded grants. She is (co)-author of more than 180 articles, and published in amongst others Translational, Biological and Molecular Psychiatry, Cerebral Cortex, Neuroscience Biobehavioral Reviews, PNAS, Journal of Neuroscience and Nature Genetics.
Maja Jagodic

Department of Clinical Neuroscience (CNS), Center for Molecular Medicine (CMM), Karolinska Institutet (KI),
Stockholm, Sweden

More

✖

Maja Jagodic

Maja Jagodic completed her MSc degree at the University of Belgrade, Serbia in Molecular Biology and Physiology specializing in Experimental Medicine in 1999. She then moved to Sweden where she obtained her PhD degree at the Karolinska Institutet studying genetic predisposition to autoimmune diseases in model organisms in 2004. After thesis defense, she spent a year at the Karolinska Institutet gaining skills in human genetics. Already towards the end of her PhD thesis, Maja became fascinated by the field of epigenetics. Epigenetic mechanisms, that orchestrate genome activity in response to environmental cues, were at that time strongly implicated in the etiology of complex inflammatory diseases but virtually unexplored. Maja was awarded a postdoctoral fellowship to study epigenetic mechanisms in cancer at the University of Cambridge, UK. In 2008, she was awarded an Assistant Professor position by the Swedish Research Council and she returned to Sweden to initiate studies of epigenetic mechanisms in Multiple Sclerosis. She was appointed a group leader position at the Department of Clinical Neuroscience at the Karolinska Institutet in 2012 and she became an Associate Professor in Experimental Medicine in 2014. Her research group continues to utilize functional genetic approaches to study mechanisms underlying chronic inflammation in the brain with a focus on Multiple Sclerosis and its experimental models.
Martin Kaczocha

Stony Brook University,
NY, USA

✖

Martin Kaczocha
Liubov Kalinichenko

University Clinic
Friedrich-Alexander-University of Erlangen-Nuremberg
Erlangen, Germany

More

✖

Liubov Kalinichenko

Dr. Liubov S. Kalinichenko graduated with the M.S. degree in pharmacy from the I.M. Sechenov First Moscow State Medical University (Russia) in 2009. In 2012, she received a Ph.D. degree in medicine from the P.K. Anokhin Institute of Normal Physiology (Russia) for her research on the role of cytokines in the regulation of oxidative and antioxidant processes in the rat brain during acute emotional stress. In 2017, she was also awarded a Ph.D. degree in neuroscience from the University Clinic Erlangen (Germany) for the investigation of the role of acid sphingomyelinase in depression/anxiety-induced alcohol addiction. This work got the Shimon Gatt Award in 2019. Since 2017, Dr. Kalinichenko is working as a postdoctoral scientist in the University Clinic Erlangen. Her primary research interests include the involvement of lipids in the mechanisms of depression-induced alcohol addiction.
Johannes Kirchmair

University of Vienna,
Vienna, Austria

✖

Johannes Kirchmair
Ewelina Knapska

Nencki Institute of Experimental Biology of Polish Academy of Sciences,
Warsaw, Poland

More

✖

Ewelina Knapska

Ewelina Knapska obtained MSc degrees in biology and psychology from the University of Warsaw. In 2001 she started working with Tomasz Werka and Leszek Kaczmarek, studying the heterogeneity of the amygdala in control of positive and negative emotions. After obtaining her PhD from the Nencki Institute of Experimental Biology PAS in 2006, Ewelina moved to Ann Arbor, USA for a postdoc in the laboratory of Prof. Stephen Maren at the University of Michigan, where she studied mechanisms of fear extinction. She moved back to Poland in 2008, getting a stipend from the Foundation for Polish Science and becoming an assistant professor at the Nencki Institute of Experimental Biology PAS. In 2012, she obtained habilitation (DSc) and became an associate professor and the head of the newly created Laboratory of Neurobiology of Emotions. In 2016 she received a Starting Grant from the European Research Council for studying the role of the amygdala in control of socially transferred emotions. Since 2018 she is Vice-President of Centre of Excellence for Neural Plasticity and Brain Disorders (BRAINCITY) in the Nencki Institute of Experimental Biology.
Michał Korostyński

Maj Institute of Pharmacology Polish Academy of Sciences,
Krakow, Poland

More

✖

Michał Korostyński

A graduate (biotechnology) of the University of Silesia of Katowice, PhD (medical science) at the Maj Institute of Pharmacology, PAS. Currently employed at the Institute of Pharmacology, where he is conducting research in the Department of Molecular Neuropharmacology. Main research interests: gene expression regulation in the brain, genome-based treatment personalization, and genetics of complex behavioral traits and diseases. Research experience: analysis and interpretation of gene expression alterations obtained using high-throughput methods, animal and cellular models of disorders of the nervous system, and molecular profiling of psychotropic drugs. In the last few years, he has been involved in the analysis of genome-sequencing data from patients with rare diseases. He has been the principal investigator of several completed research grants and R&D projects, (co-) author of 91 publications cited 1584 times, H-index 22. He is the Field Editor of the Pharmacological Research journal.
Beat Lutz

University Medical Center of the Johannes Gutenberg, University Mainz,
Mainz, Germany

More

✖

Beat Lutz

Since 1997, his group has dissected the diverse functions of endocannabinoid system and the cannabinoid CB1 receptor in different cell types and organ systems, by using the Cre/loxP system in mouse. Thereby, they have made major contributions to the mechanistic understanding of this lipid signaling system in fear and anxiety circuits, in stress coping, in neuroprotection and in the regulation of the brain’s neuronal excitability, in the fine-tuned regulation of synaptic transmission and homeostatic processes, and in neural development. They found a dichotomic function of CB1 receptor in the brain’s excitatory and inhibitory neurons in signaling, synaptic transmission and behavioral regulation. They furthermore contributed to the mechanistic underpinnings on how cannabinoids and endocannabinoid degradation inhibitors employ their effects, thus, promoted our insights into the beneficial and adversive effects of cannabinoids in health and disease, an important current issue in society.

His research fueled many other aspects of endocannabinoid research, whereby they have crucially been involved in. These studies include: olfactory perception, pain perception, spasticity in multiple sclerosis mouse models and the therapeutic potential of cannabis in this neurodegenerative disease, cannabis actions / endocannabinoid fuctions on neural developmentin endocannabinoid functions in several peripheral organs, including liver, involvement in the regulation of energy balance and feeding, discovery of CB1 receptor in mitochondria, discovery of novel endocannabinoid-like compounds, such as pepcan and lipoxin A4.

In summary, Prof. Lutz has given numerous novel insights into this body’s signaling system, and his discoveries have had important impacts on the field of endocannabinoid research, but also on neurosciences and physiology in general.
Vincenzo Di Marzo

Université Laval,
Canada, Italy

✖

Vincenzo Di Marzo
Adrian Newman-Tancredi

Swansea University,
Swansea, UK

More

✖

Adrian Newman-Tancredi

Adrian Newman-Tancredi, PhD, DSc, is a researcher with over 25 years’ experience of neuroscience drug discovery and early development. He is Co-Founder and Chief Executive Officer of a bioscience company, Neurolixis, developing clinical-stage drugs for treatment of Parkinson’s disease and other neurological disorders. Previously, he was Director of Neurobiology drug discovery at Pierre Fabre Laboratories, identifying novel antipsychotic, antidepressant and analgesic drug candidates. Prior to Pierre Fabre, Adrian Newman-Tancredi characterized the serotonergic properties of atypical antipsychotics and antiparkinsonian drugs and investigated signal transduction of monoamine receptors at the Servier Research Institute. Dr Newman-Tancredi has published over 180 articles in peer-reviewed journals, is co-inventor on a dozen patents and serves as European Councilor for the International Society for Serotonin Research. His principal current focus is the development of the first-in-class serotonergic ‘biased agonists’ befiradol (NLX-112) and NLX-101 (F15599), having previously characterized several approved drugs, including milnacipran (Savella ®), piribedil (Trivastal ®), agomelatine (Valdoxan ®) and levomilnacipran (Fetzima ®).
Nicholas Pintori

University of Verone,
Verona, Italy

More

✖

Nicholas Pintori

Nicholas Pintori, MSc, PhD is a Post Doctoral researcher at the Neuropsychopharmacology division of the University in Cagliari. Nicholas Pintori is author of more than 10 publications in International Scientific Journals and Books, and his main research interest involves the study of the neurochemical, behavioral, and glial alterations induced by repeated exposure to synthetic cannabinoids, in particular JWH-018, and other classes of the so-called “novel psychoactive substances”. Other lines of research involve the study of the mechanism underlying the addiction, specifically the reactivation and the reconsolidation of maladaptive memories in rodents with a history of food or drug self-administration, and the study of the effect of enriched environment on food and drugs relapse in rodents.
Arkadiusz Piotrowski

Medical University of Gdańsk,
Gdansk, Poland

✖

Arkadiusz Piotrowski
Rafał Płoski

Medical University of Warsaw,
Warsaw, Poland

✖

Rafał Płoski
Didier Rognan

Université de Strasbourg,
Strasbourg, France

✖

Didier Rognan
Janusz Rybakowski

Poznan University of Medical Sciences,
Poznan, Poland

More

✖

Janusz Rybakowski

Prof. Janusz K. Rybakowski was the Head of Department of Adult Psychiatry, Poznan University of Medical Sciences, 1995-2016, the Chairman, Department of Psychiatry, Medical Academy, Bydgoszcz, 1985-1995, the NIH Fogarty Research Fellow, Department of Psychiatry, University of Pennsylvania, Philadelphia, 1976-1977. He was the President of the Polish Psychiatric Association, 1998-2001, a Board Member of the Association of European Psychiatrists, 1998-2004, and has been a member of ten other international scientific associations.

Prof. Rybakowski authored over 600 scientific articles on clinical psychiatry, neurobiology, and psychopharmacology, present Hirsch Index 55. He is the author of the books “The Faces of Manic-Depressive Illness” (2009) and “Lithium – the Amazing Drug in Psychiatry” (2020). He has been a member of the Editorial Board of 16 international journals. He is the only Polish psychiatrist among the top 2% scientists, according to recent report by the Stanford University and Elsevier.

In 2012, Prof. Rybakowski received the Lifetime Achievement Award of the European Bipolar Forum, in 2015, the Lifetime Achievement Award in Biological Psychiatry of the World Federation of the Societies of Biological Psychiatry, and in 2018, the Mogens Schou scientific award of the International Society of Bipolar Disorders.
Tomasz Rzymski

Ryvu Therapeutics,
Krakow, Poland

✖

Tomasz Rzymski
Maria M. Sąsiadek

Wroclaw Medical University,
Wroclaw, Poland

✖

Maria M. Sąsiadek
Marcin Siwek

Jagiellonian University Medical College,
Krakow, Poland

✖

Marcin Siwek
Anna Sobczak

Jagiellonian University,
Krakow, Poland

✖

Anna Sobczak
Nicola Simola

University of Cagliari,
Cagliari, Italy

✖

Nicola Simola
Rebecca Strawbridge

King’s College London,
London, UK

✖

Rebecca Strawbridge
Róża Szweda

Lukasiewicz Research Network –PORT, Polish Centre of Technology Development,
Wroclaw, Poland

✖

Róża Szweda
Łukasz Święcicki

Institute of Psychiatry and Neurology,
Warsaw, Poland

✖

Łukasz Święcicki
Paul Willner

Swansea University,
Swansea, UK

✖

Paul Willner
Jacek R. Wiśniewski

Max Planck Institute of Biochemistry,
Martinsried, Germany

✖

Jacek R. Wiśniewski
Markus Wöhr

Philipps-University of Marburg,
Marburg, Germany

More

✖

Markus Wöhr

Markus Wöhr, Dr. rer. nat. (PhD), is a psychologist and behavioral neuroscientist, presently working as Professor for Biological Psychology and Behavioral Pharmacology at the Faculty of Psychology and Educational Sciences, KU Leuven, Belgium. He is the head of the Social and Affective Neuroscience Research Group. Markus Wöhr has a broad background in animal behavior and translational research models for neuropsychiatric dysfunctions, with specific training and expertise in behavioral neuroscience of affective and neurodevelopmental disorders. His main research interests include neurobiological mechanisms underlying social behavior, acoustic communication through ultrasonic vocalizations, and socio-affective information processing in rodents.

- 09.00 – 9.10 a.m.
  
  Welcome message
  
  Chairs: Honorary Committee & Organizing Committee
- 9.10 – 10.00 a.m.
  10.00 – 10.10 a.m. chat
  A
  
  Plenary lecture 1
  
  Inaugural lecture
  
  Francesco Pavone
  University of Florence, Florence, Italy
  Human brain optical mapping
  
  Professor Władysław Lasoń, PhD
- 10.30 a.m.– 12.20 p.m.
  12.20 – 12.30 p.m. chat
  A
  
  Session 1
  
  Covid-19 pandemic
  
  Professor Marek Sanak, PhD
- 10.30 a.m. – 12.20 p.m.
  12.20 – 12.30 p.m. chat
  B
  Session 2
  
  Chem- and bioinformatics in drug design
  - S.02-1
    Didier Rognan
    Université de Strasbourg, Strasbourg, France
    Designing a truly unbiased dataset for machine learning and virtual screening
  - S.02-2
    Johannes Kirchmair
    University of Vienna, Vienna, Austria
    Computational methods for flagging compounds likely to cause false outcomes in biological assays
  - S.02-3
    Tomasz Rzymski
    Ryvu Therapeutics, Krakow, Poland
    Identification of Actionable Protein Targets for Cancer Therapy by Integrated Analysis of Next-Generation Sequencing Data and High-Content Genomic Interrogation Screens
  Professor Andrzej Bojarski, PhD
- 1.00 – 2.50 p.m.
  2.50 – 3.00 p.m. chat
  A
  Session 3
  
  Clinical genomics
  - S.03-1
    Rafał Płoski
    Medical University of Warsaw, Warsaw, Poland
    Whole exome and genome sequencing for discovery of novel human diseases
  - S.03-2
    Maciej Giefing
    Institute of Human Genetics Polish Academy of Sciences, Poznan, Poland
    New (epi)genetic diagnostic tools for cancer – liquid biopsy and beyond
  - S.03-3
    Maria M. Sąsiadek
    Wroclaw Medical University, Wrocław, Poland
    Multigene panel testing in oncology clinical practice – pros and cons
  - S.03-4
    Arkadiusz Piotrowski
    Medical University of Gdańsk, Gdańsk, Poland
    Somatic driver mutations in normal mammary tissue from breast cancer patients – incidental or causal?
  Michał Korostyński, PhD
  Michał Dąbrowski, PhD
- 1.00 – 2.50 p.m.
  2.50 – 3.00 p.m. chat
  B
  Session 4
  
  Discovery of biomarkers in mental disorders
  - S.04-1
    Gordana Nedic Erjavec
    Ruđjer Bošković Institute, Zagreb, Croatia
    Biomarkers of schizophrenia
  - S.04-2
    Rebecca Strawbridge
    King’s College London, London, UK
    What’s the use of biomarkers for depression?
  - S.04-3
    Andreas Grabrucker
    University of Limerick, Limerick, Ireland
    Zinc deficiency and affected signalling networks as biomarkers and causative factors of Autism Spectrum Disorders
  Bernadeta Szewczyk, PhD
  Andreas Grabrucker, PhD
- 3.30 – 5.20 p.m.
  5.20 – 5.30 p.m. chat
  A
  Session 5
  
  Presentations from ERC grant awardees
  - S.05-1
    Maja Jagodic
    Karolinska Institutet, Stockholm, Sweden
    Applied epigenomics: insights into the pathogenesis of Multiple Sclerosis
  - S.05-2
    Jan Gründemann
    University of Basel, Basel, Switzerland
    Imaging deep: Sensory and state coding in subcortical circuits
  - S.05-3
    Ewelina Knapska
    Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland
    Neuronal circuits of motivation for food rewards and social interaction
  Jan Manuel Rodriguez Parkitna, PhD
- 9.00 a.m. – 5.30 p.m.
  
  Poster session
- 9.00 – 9.10 a.m.
  
  Opening of the 2^nd day of the CEBC
- 9.10 – 11.00 a.m.
  11.00 – 11.10 a.m. chat
  A
  Session 6
  
  Perspectives for therapy of treatment-resistant depression
  - S.06-1
    Wiesław J. Cubala
    Medical University of Gdansk, Poland
    New developments in understanding mechanisms of drug resistance in the treatment of depression
  - S.06-2
    Łukasz Święcicki
    Institute of Psychiatry and Neurology, Warsaw, Poland
    Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS
  - S.06-3
    Paul Willner
    Swansea University, Swansea, UK
    Pharmacological and optogenetic studies on mechanisms of resistance to antidepressant drugs in animal models of treatment-resistant depression
  - S.06-4
    Adrian Newman-Tancredi
    Neurolixis Inc., Wilmington, DE 19808, USA
    Cortical 5-HT1A receptor biased agonism – a novel mechanism for effective therapy of treatment-resistant depression
  Professor Mariusz Papp, Ph.D Professor Paul Willner, PhD
- 9.10 – 11.00 a.m.
  11.00 – 11.10 a.m. chat
  B
  Session 7
  
  Neuroimaging – beyond the structure
  - S.07-1
    Bogdan Draganski
    University of Lausanne, Lausanne, Switzerland
    MRI-based in vivo histology – myth or reality
  - S.07-2
    Adrian Chrobak
    Jagiellonian University Medical College, Krakow, Poland
    Time-frequency dynamics of resting state in euthymic bipolar disorder patients – a preliminary fMRI study
  - S.07-3
    Anna Ceglarek
    Jagiellonian University, Krakow, Poland
    Reduced regional homogenity after intraocular lens (IOL) implantation – restingstate fMRI study
  - S.07-4
    Anna Sobczak
    Jagiellonian University, Krakow, Poland
    Functional connectivity differences in Salient Network among euthymic bipolar disorder patients in regard to suicide risk; a preliminary fMRI study
  Professor Joanna Pera, PhD, Professor Tadeusz Marek, PhD
- 11.30 a.m.– 12.20 p.m.
  12.20 – 12.30 p.m. chat
  A
  
  Plenary lecture 2
  
  Professor Francesco Battaglia
  Radboud University, Nijmegen, The Netherlands
  The lifetime of memories: processing and reprocessing of information in the brain
  
  Professor Małgorzata Filip, PhD
- 1.00 – 2.50 p.m.
  2.50 – 3.00 p.m. chat
  A
  Session 8
  
  The role of serotonin in neurodevelopmental disorders
  - S.08-1
    Judith Homberg
    Radboud University, Nijmegen Medical Centre, Nijmegen, the Netherlands
    The role of serotonin in brain development and behaviour: the SSRI and efavirenz cases
  - S.08-2
    Francesca Calabrese
    University of Milan, Milan, Italy
    Stress exposure as a risk factor for the development of psychiatric disorders: a role for the serotoninergic system
  - S.08-3
    Natalia Alenina
    Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Maternal and central serotonin: contribution to the early development in rodents
  - S.08-4
    Markus Wöhr
    Philipps-University of Marburg, Marburg, Germany
    Affective communication in rodents: serotonin and its modulating role in ultrasonic vocalizations
  Professor Piotr Popik, PhD
  Agnieszka Nikiforuk, PhD
  Professor Judith Homberg, PhD
- 1.00 – 2.50 p.m.
  2.50 – 3.00 p.m. chat
  B
  Session 9
  
  Biological context of bipolar disorder
  - S.09-1
    Dominika Dudek
    Jagiellonian University Medical College, Krakow, Poland
    Chronobiology and social rythms in bipolar disorders
  - S.09-2
    Janusz Rybakowski
    Poznan University of Medical Sciences, Poznan, Poland
    Lithium: mechanisms of action in association with BD neurobiology
  - S.09-3
    Marcin Siwek
    Jagiellonian University Medical College, Krakow, Poland
    Biomarkers of staging in BD
  - S.09-4
    Adrian Chrobak
    Jagiellonian University Medical College, Krakow, Poland
    Neurocognitive and motor deficits in BD – neuroimaging and clinical studies
  Professor Dominika Dudek, MD
- 3.30 – 5.30 p.m.
  
  Workshops
- 9.00 a.m. – 5.30 p.m.
  
  Poster session
- 9.00 – 9.10 a.m.
  
  Opening of the 3^rd day of the CEBC
- 9.10 – 10.00 a.m.
  10.00 – 10.10 chat
  A
  
  Plenary lecture 3
  
  Professor, Jacek R. Wiśniewski, PhD
  Max Planck Institute of Biochemistry, Martinsried, Germany
  Large scale proteomics for understanding biological systems
- 10.20 a.m. – 12.10 p.m.
  12.10 – 12.20 p.m. chat
  A
  Session 10
  
  Computational personalised medicine
  - S.10-1
    Marian Bubak
    Sano Centre for Computational Medicine, Krakow and AGH University of Science and Technology, Krakow, Poland
  - S.10-2
    Róża Szweda
    Lukasiewicz Research Network –PORT, Polish Centre of Technology Development, Wrocław, Poland
    Sequence-defined polymers – a next generation data storage medium
  - S.10-3
    Zbigniew Szewczuk
    University of Wrocław, Wrocław, Poland
    Using markers in targeted diagnostics
  Marian Bubak, PhD
  Przemysław Mielczarek, PhD
- 10.20 a.m. – 12.10 p.m.
  12.10 – 12.20 p.m. chat
  B
  Session 11
  
  Genes affect your risk for addiction
  - S.11-1
    Lucia Caffino
    Università degli Studi di Milano, Milano, Italy
    Effects of cocaine self-administration on neuroplastic mechanisms: evidence from rats lacking the serotonin transporter
  - S.11-2
    Judith Homberg
    Radboud University Medical Center, Nijmegen, The Netherlands
    The neural mechanisms driving the transition from regular to compulsive cocaine intake in rats lacking the serotonin transporter
  - S.11-3
    Liubov Kalinichenko
    University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany
    Sphingolipids in depression-induced alcoholism
  - S.11-4
    Giuseppe Giannotti
    University of Colorado Denver, Aurora, CO, USA
    Paraventricular thalamic control of opioid withdrawal and relapse
  Małgorzata Frankowska, PhD
  Irena Smaga-Maślanka, PhD
  Lucia Caffino, PhD
- 1.00 – 1.50 p.m.
  1.50 – 2.00 p.m. chat
  A
  
  Plenary lecture 4
  
  Professor, David E. Nichols, PhD
  Purdue University College of Pharmacy, West Lafayette, LA, USA
  Psychedelic Research in the 21st Century
  
  Professor Krystyna Gołembiowska, PhD
- 2.30 –4.20 p.m.
  4.20 – 4.30 p.m. chat
  A
  Session 12
  
  Novel views on psychoactive and additive drugs
  - S.12-1
    Kathryn A. Cunningham
    University of Texas Medical Branch, Galveston, USA
    Defining and Mining Therapeutic Targets in Psychostimulant Use Disorders
  - S.12-2
    Nicola Simola
    University of Cagliari, Cagliari, Italy
    The novel psychoactive substance methoxetamine induces persistent behavioral abnormalities and neurotoxicity: a study in rats
  - S.12-3
    Nicholas Pintori
    University of Verone, Verona, Italy
    Dopamine system dysregulation, glial cells alteration, and behavioral correlates after repeated exposure to the synthetic cannabinoid receptor agonist JWH-018
  - S.12-4
    Giulia Costa
    University of Cagliari, Cagliari, Italy
    Mechanisms and neurotransmitter systems involved in the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) administration during adolescence.
  Professor Krystyna Gołembiowska, PhD
  Professor Kathryn A. Cunningham, PhD
- 2.30 –4.20 p.m.
  4.20 – 4.30 p.m. chat
  B
  Session 13
  
  Endocannabinoid signaling in health and disease
  - S.13-1
    Vincenzo Di Marzo
    Université Laval, Canada, Italy
    Bidirectional interaction between the gut microbiome and the endocannabinoidome
  - S.13-3
    Martin Kaczocha
    Stony Brook University, NY, USA
    FABP5 as a Trans-Synaptic Carrier for Endocannabinoids
  - S.13-4
    Beat Lutz
    University Medical Center of the Johannes Gutenberg, University Mainz, Mainz, Germany
    Anandamide Signaling in Stress Coping: For Good or Bad?
  Katarzyna Starowicz – Bubak, PhD
  Professor Beat Lutz, PhD
- 4.45 – 5.45 p.m.
  A
  
  Session 14
  
  Young scientific investigators’ session
  
  S.14-1-10
  
  Rafał Ryguła, PhD
  Karolina Noworyta, PhD
- 5.45 – 6.00 p.m.
  
  Closing & Award ceremony
  
  Professor Małgorzata Filip, PhD
  Professor Joanna Pera, PhD

Registration

Given the circumstances, CEBC has offered the virtual congress at a significantly reduced price.

The virtual platform offered access to:

The full programme: live sessions, sessions with Q&A and on-demand sessions
Interactive e-posters with opportunities to chat with presenters,
Workshops (registration will be open at the end of April 2021),
Exhibition stands,
Networking opportunities.

All sessions, including ePosters and exhibition stands, will be available for

Registration fees

Member

Regular

Early Career Scientists*, Students
Early
fee

(until 1 May 2021)

Regular:

300 PLN
65.87 €

Early Career Scientists*, Students:

150 PLN
32.94 €
Standard
fee

(until 1 june 2021)

Regular:

350 PLN
76.85 €

Early Career Scientists*, Students:

200 PLN
43.91 €
Late
fee

(after 1 June 2021)

Regular:

400 PLN
87.83 €

Early Career Scientists*, Students:

250 PLN
54.89 €

Fees are quoted in zloty (PLN), per person. Payments in other currencies are not accepted. Please see Currency Converter to check the price in other currencies.

* Definition of an Early Career Scientist – a person who has had a doctoral degree for a period not exceeding 7 years.

Sponsors
& exhibition packages

>> Sponsors
- Virtual Booth
- Premium Plus
- Premium
- 3000 PLN
- 2500 PLN
- Logotype exposure in Sponsors / Exhibition section on the platform (no. tiles per row)
- full size
- 1/2 size
- Size of thumbnail redirecting to a chosen booth (no. thumbnails per row)
- full size
- 1/2 size
- Sponsor / Exhibitor badges
- 4
- 4
- Company name and logo on Congress Website
- ✓
- ✓
- Product brochure (documents and images)
- ✓
- ✓
- Play uploaded media (single file or a playlist)
- ✓
- ✓
- Communicate with visitors via text chat or a videocall
- ✓
- ✓
- Promo materials for download
- ✓
- ✓
- Company presentation during advertising block on a main stage
- ✓*
- ✓**
* ads limited to 3 min; ** ads limited to 1 min
Please note that VAT tax should be settled in the country where your company is registered
>> Exhibition
- Virtual Booth
- Gold
- Silver
- Bronze
- 2000 PLN
- 1500 PLN
- 1000 PLN
- Logotype exposure in Sponsors / Exhibition section on the platform (no. tiles per row)
- 1/2 size
- 1/3 size
- 1/4 size
- Size of thumbnail redirecting to a chosen booth (no. thumbnails per row)
- 1/2 size
- 1/3 size
- 1/4 size
- Sponsor / Exhibitor badges
- 3
- 2
- 1
- Company name and logo on Congress Website
- ✓
- ✓
- ✓
- Product brochure (documents and images)
- ✓
- ✓
- ✓
- Play uploaded media (single file or a playlist)
- ✓
- ✓
- ✓
- Communicate with visitors via text chat or a videocall
- ✓
- ✓
- ✓
- Promo materials for download
- ✓
- ✓
- ✓
Please note that VAT tax should be settled in the country where your company is registered

Abstract submission
& guidelines

Prior to submitting the abstract the presenting Author needs to be registered (including payment) at the Congress: www.cebc.pl. The deadline for an Abstract submission is 30^th April, 2021.

RULES FOR SUBMISSION OF ABSTRACTS:

Abstracts must be submitted via this website. Faxed or emailed abstracts will not be considered.

All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. The abstract should be written using Calibri at 12 points and applying single spacing. The abstract needs to be submitted in Word document (doc, docx or rtf) format.

All abstracts accepted for presentation will be published on the Congress website prior to the Congress.

You may submit only 1 abstract. Presenters that are accepted for oral presentation will be permitted to give only 1 oral presentation.

The abstracts will be published in the Book of Abstracts as an eBook.

The abstract successfully submitted will be confirmed by e-mail.

ABSTRACT SELECTION AND PRESENTATION

The Scientific Committee will review all submitted abstracts. Notification regarding abstract acceptance and scheduling will be sent to the submitting Author. The confirmation about abstract accepted to oral presentation will be send by email before 7^th may 2021.

SUBMIT YOUR ABSTRACT

British Journal
of Pharmacology

Welcome to read a special issue of British Journal of Pharmacology!

You can find several high-quality articles of our Lecturers!

Themed Issue: New discoveries and perspectives in mental and pain disorders.

Invitation to submit articles
to Pharmacological Reports

Invitation to submit articles <br />
to Pharmacological Reports

Pharmacological Reports (ISSN 1734-1140) is the official journal of Maj Institute of Pharmacology Polish Academy of Sciences published with Springer Nature.

Pharmacological Reports is an open forum for recent developments in experimental and clinical pharmacology, dealing with the action of drugs at cellular, molecular and behavioral levels.

It publishes research articles, reviews, and short communications. The journal guarantees rapid publication of accepted papers, comprised of fast acceptance and publication for articles. It is a hybrid journal, offering the choice of open access, and is published bi-monthly.

For more information, please visit the journal’s homepage https://www.springer.com/journal/43440

Scientific
committee

Name
Institution
Country

Andrzej Bojarski

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Lucia Caffino

Università degli Studi di Milano
Milano

Italy
Francesca Calabrese

University of Milan
Milan

Italy
Kathryn A. Cunningham

University of Texas Medical Branch
Galveston

USA
Michał Dąbrowski

Nencki Institute of Experimental Biology of Polish Academy of Sciences
Warsaw

Poland
Dominika Dudek

Jagiellonian University Medical College
Krakow

Poland
Małgorzata Filip

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Małgorzata Frankowska

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Giuseppe Giannotti

University of Colorado Denver
Aurora
CO

USA
Andreas Grabrucker

University of Limerick
Limerick

Ireland
Judith Homberg

Radboud University
Nijmegen Medical Centre
Nijmegen

Netherlands
Martin Kaczocha

Stony Brook University
NY

USA
Liubov Kalinichenko

University Clinic
Friedrich-Alexander-University of Erlangen-Nuremberg
Erlangen

Germany
Beat Lutz

University Medical Center of the Johannes Gutenberg
University Mainz
Mainz

Germany
Irena Nalepa

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Agnieszka Nikiforuk

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Rafał Olszanecki

Jagiellonian University Medical College
Krakow

Poland
Mariusz Papp

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Jan Rodriguez Parkitna

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Joanna Pera

Jagiellonian University Medical College
Krakow

Poland
Piotr Popik

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Edmund Przegaliński

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Didier Rognan

Université de Strasbourg
Strasbourg

France
Irena Smaga-Maślanka

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Katarzyna Starowicz-Bubak

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Bernadeta Szewczyk

Maj Institute of Pharmacology Polish Academy of Sciences
Krakow

Poland
Paul Willner

Swansea University
Swansea

UK

Organizing
committee

Małgorzata Filip

Professor, PhD

Function:
Chair

Maj Institute of Pharmacology
Polish Academy of Sciences
Joanna Pera

Professor, PhD, MD

Function:
Program Chair, Guest Speakers

Medical College
Jagiellonian University

Remaining
organizers

Name
Function
Institution
Country
Email

Małgorzata Frankowska, PhD

Company Exhibition, Sponsors

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland
Irena Smaga-Maślanka, PhD

Public Relations

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland
Dawid Gawliński, PhD

Media

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland
Karolina Wydra, PhD

Publications

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland
Agata Faron–Górecka, PhD

Company Exhibition, Sponsors

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland
Agata Suder

General Secretarial Duties

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland
Kamila Piotrowska, MSc

Guest Speaker

Maj Institute of Pharmacology
Polish Academy of Sciences

Poland

Patronage

Honorary Patronage

We are very pleased to announce that following persons took the honorary patronage over the 4^th Central European Biomedical Congress:

Jacek Popiel

Professor, Ph.D

Rector of the Jagiellonian University

Honorary Committee

Tomasz Grodzicki

Professor, Ph.D, MD

Vice Rector of Medical College
Collegium Medicum
Jagiellonian University
Władysław Lasoń

Professor, Ph.D

Former director of the Maj Institute of Pharmacology
Polish Academy of Sciences
Maciej Małecki

Professor, Ph.D, MD

Dean of the Faculty of Medicine
Collegium Medicum
Jagiellonian University

4TH Central European Biomedical Congress

Welcomeaddress

Małgorzata Filip

Joanna Pera

About the Event

CEBC 2021 is dedicated to:

Plenaryspeakers

Professor, David E. Nichols, PhD

Professor, David E. Nichols, PhD

Professor, Francesco Pavone, PhD

Professor, Francesco Pavone, PhD

Professor, Francesco Battaglia, PhD

Professor, Francesco Battaglia, PhD

Professor, Jacek R. Wiśniewski, PhD

Professor, Jacek R. Wiśniewski, PhD

Speakers

Natalia Alenina

Natalia Alenina

Marian Bubak

Marian Bubak

Lucia Caffino

Lucia Caffino

Francesca Calabrese

Francesca Calabrese

Anna Ceglarek

Anna Ceglarek

Adrian Chrobak

Adrian Chrobak

Giulia Costa

Giulia Costa

Wiesław J. Cubala

Wiesław J. Cubala

Kathryn A. Cunningham

Kathryn A. Cunningham

Bogdan Draganski

Bogdan Draganski

Dominika Dudek

Dominika Dudek

Gordana Nedic Erjavec

Gordana Nedic Erjavec

Giuseppe Giannotti

Giuseppe Giannotti

Maciej Giefing

Maciej Giefing

Andreas Grabrucker

Andreas Grabrucker

Jan Gründemann

Jan Gründemann

Judith Homberg

Judith Homberg

Maja Jagodic

Maja Jagodic

Martin Kaczocha

Martin Kaczocha

Liubov Kalinichenko

Liubov Kalinichenko

Johannes Kirchmair

Johannes Kirchmair

Ewelina Knapska

Ewelina Knapska

Michał Korostyński

Michał Korostyński

Beat Lutz

Beat Lutz

Vincenzo Di Marzo

Vincenzo Di Marzo

Adrian Newman-Tancredi

Adrian Newman-Tancredi

Nicholas Pintori

Nicholas Pintori

Arkadiusz Piotrowski

Arkadiusz Piotrowski

Rafał Płoski